The Goldman Sachs Group Increases Enliven Therapeutics (NASDAQ:ELVN) Price Target to $80.00

Enliven Therapeutics (NASDAQ:ELVN) had its price objective increased by research analysts at The Goldman Sachs Group from $67.00 to $80.00 in a research note issued on Thursday,Benzinga reports. The firm currently has a “buy” rating on the stock. The Goldman Sachs Group’s price objective would indicate a potential upside of 32.32% from the company’s previous close.

Other equities analysts also recently issued reports about the company. Stifel Nicolaus lifted their target price on Enliven Therapeutics from $60.00 to $80.00 and gave the company a “buy” rating in a research report on Wednesday, July 1st. Mizuho raised their price objective on shares of Enliven Therapeutics from $45.00 to $62.00 and gave the company an “outperform” rating in a research note on Tuesday, June 2nd. HC Wainwright lifted their price objective on shares of Enliven Therapeutics from $56.00 to $64.00 and gave the company a “buy” rating in a report on Thursday, July 9th. Guggenheim assumed coverage on shares of Enliven Therapeutics in a research note on Tuesday, May 12th. They set a “buy” rating and a $80.00 target price on the stock. Finally, Wall Street Zen upgraded shares of Enliven Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, May 11th. Six analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $72.67.

Enliven Therapeutics Stock Up 0.3%

ELVN opened at $60.46 on Thursday. Enliven Therapeutics has a 52 week low of $14.78 and a 52 week high of $62.32. The business has a fifty day simple moving average of $48.62 and a 200-day simple moving average of $39.68. The firm has a market cap of $3.68 billion, a P/E ratio of -36.20 and a beta of 0.27.

Enliven Therapeutics (NASDAQ:ELVN) last posted its quarterly earnings data on Wednesday, August 5th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.10). Sell-side analysts expect that Enliven Therapeutics will post -1.57 earnings per share for the current year.

Insider Activity

In other news, CFO Benjamin Hohl sold 6,018 shares of the business’s stock in a transaction dated Friday, July 17th. The stock was sold at an average price of $52.64, for a total transaction of $316,787.52. Following the completion of the transaction, the chief financial officer directly owned 46,054 shares of the company’s stock, valued at approximately $2,424,282.56. The trade was a 11.56% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Lori Anne Kunkel sold 10,000 shares of the company’s stock in a transaction that occurred on Friday, June 5th. The stock was sold at an average price of $34.54, for a total transaction of $345,400.00. Following the sale, the director owned 51,884 shares in the company, valued at $1,792,073.36. The trade was a 16.16% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 190,831 shares of company stock worth $10,991,723. 3.00% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Enliven Therapeutics

Large investors have recently modified their holdings of the company. KBC Group NV purchased a new stake in shares of Enliven Therapeutics during the 1st quarter worth $38,000. Mirae Asset Global Investments Co. Ltd. increased its holdings in Enliven Therapeutics by 25.9% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,884 shares of the company’s stock valued at $44,000 after buying an additional 594 shares during the last quarter. BNP Paribas Financial Markets raised its stake in Enliven Therapeutics by 33.3% in the second quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company’s stock valued at $75,000 after buying an additional 930 shares in the last quarter. Los Angeles Capital Management LLC acquired a new stake in Enliven Therapeutics in the fourth quarter valued at $83,000. Finally, Quantbot Technologies LP lifted its holdings in Enliven Therapeutics by 47.1% during the 2nd quarter. Quantbot Technologies LP now owns 4,477 shares of the company’s stock worth $90,000 after buying an additional 1,434 shares during the last quarter. 95.08% of the stock is owned by hedge funds and other institutional investors.

About Enliven Therapeutics

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.